An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

Independence Blue Cross said starting Jan. 1 it will only be covering GLP-1 agonists — commonly sold under brand names like ...

CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...

Ozempic is a drug for diabetes, but it's also being used off-label for weight loss. Its active ingredient has inspired a new ...

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...

Ozempic and Wegovy, made by Novo, are on track to become the world’s top-selling drugs by 2025. Yet in 2024, ‘Wegovy Wednesday’ had already become one of the biggest weight-loss trends to sweep the ...

Novo's Ozempic is approved by the U.S. Food and Drug Administration (FDA) to treat diabetes, while Wegovy is primarily ...

A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...